Berberine inhibits the expression of hypoxia induction factor-1alpha and increases the radiosensitivity of prostate cancer

Diagnostic Pathology

Volumn 9, Issue 1, 2014, Pages

  Zhang, Qu ^a   Zhang, Chi ^b   Yang, Xi ^b   Yang, Baixia ^c   Wang, Jinfeng ^a   Kang, Yahui ^a   Wang, Zhongming ^a   Li, Defan ^a   Huang, Guanhong ^a   Ma, Zhaoming ^a   Sun, Xinchen ^b   Cai, Jing ^c   Tao, Guangzhou ^d   Dai, Shengbin ^e   Mao, Weidong ^f   Ma, Jianxin ^a  

^a Department of Medical Oncology   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANTONG UNIVERSITY   (China)

^d THE AFFILIATED HUAIAN NO 1 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^e Taizhou People's Hospital   (China)

^f JIANGYIN PEOPLE S HOSPITAL   (China)

Author keywords

Berberine; HIF 1 ; Prostate cancer; Radiosensitivity

Indexed keywords

BERBERINE; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RADIOSENSITIZING AGENT; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HUMAN; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; RADIATION DOSE; RADIATION RESPONSE; TIME; TUMOR CELL LINE; UPREGULATION;

ANIMALS; APOPTOSIS; BERBERINE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE, INBRED BALB C; MICE, NUDE; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TIME FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902115999     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-9-98     Document Type: Article

References (16)

1. Wang H, Yao Y, Li B. Factors associated with the survival of prostate cancer patients with rectal involvement. Diagn Pathol 2014, 9:35. 10.1186/1746-1596-9-35, 3938032, 24555830.
2. Marcos-Gragera R, Salmerón D, Izarzugaza I, Ardanaz E, Serdà BC, Larrañaga N, San Román E, Navarro C, Chirlaque MD. Trends in prostate cancer survival in Spain: results from population-based cancer registries. Clin Transl Oncol 2012, 14:458-64. 10.1007/s12094-012-0824-0, 22634535.
3. Tomioka A, Tanaka M, De Velasco MA, Anai S, Takada S, Kushibiki T, Tabata Y, Rosser CJ, Uemura H, Hirao Y. Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. Mol Cancer Ther 2008, 7:1864-1870. 10.1158/1535-7163.MCT-07-2198, 18644998.
4. Jiang XD, Qiao Y, Dai P, Wu J, Song DA, Li SQ, Fan YW. Preliminary clinical study of weekly recombinant human endostatin as a hypoxic tumour cell radiosensitiser combined with radiotherapy in the treatment of NSCLC. Clin Transl Oncol 2012, 14:465-70. 10.1007/s12094-012-0825-z, 22634536.
5. Ikeda E. Cellular response to tissue hypoxia and its involvement in disease progression. Pathol Int 2005, 55:603-610. 10.1111/j.1440-1827.2005.01877.x, 16185289.
6. Chi KH, Wang YS, Kao SJ. Improving radioresponse through modification of the tumor immunological microenvironment. Cancer Biother Radiopharm 2012, 27:6. 10.1089/cbr.2011.1048, 22239431.
7. Ishizaki F, Hara N, Koike H, Kawaguchi M, Tadokoro A, Takizawa I, Nishiyama T, Takahashi K, Hohenfellner R. Prediction of pathological and oncological outcomes based on extended prostate biopsy results in patients with prostate cancer receiving radical prostatectomy: a single institution study. Diagn Pathol 2012, 7:68. 10.1186/1746-1596-7-68, 3449198, 22697234.
8. Tian Y, Zhao L, Zhang H, Liu X, Zhao L, Zhao X, Li Y, Li J. AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression. Diagn Pathol 2014, 9:42. 10.1186/1746-1596-9-42, 3939640, 24571686.
9. Ma L, Zhao J, Li T, He Y, Wang J, Xie L, Qin X, Li S. Association between tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis. Diagn Pathol 2014, 9:74. 10.1186/1746-1596-9-74, 3977697, 24666463.
10. Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, Gleave ME. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002, 8:3276-3284.
11. Chiu HW, Chen YA, Ho SY, Wang YJ. Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells. PLoS One 2012, 7:e31579. 10.1371/journal.pone.0031579, 3282747, 22363680.
12. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994, 13:139-168. 10.1007/BF00689633, 7923547.
13. Harada H, Itasaka S, Zhu Y, Zeng L, Xie X, Morinibu A, Shinomiya K, Hiraoka M. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer 2009, 100:747-757. 10.1038/sj.bjc.6604939, 2653764, 19223896.
14. Liu Q, Jiang H, Liu Z, Wang Y, Zhao M, Hao C, Feng S, Guo H, Xu B, Yang Q, Gong Y, Shao C. Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51. PLoS One 2011, 6:23427.
15. Orr WS, Denbo JW, Saab KR, Ng CY, Wu J, Li K, Garner JM, Morton CL, Du Z, Pfeffer LM, Davidoff AM. Curcumin potentiates rhabdomyosarcoma radiosensitivity by suppressing NF-kB activity. PLoS One 2013, 8:51309.
16. Peng PL, Kuo WH, Tseng HC, Chou FP. Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer: the contribution of autophagic cell death. Int J Radiat Oncol Biol Phys 2008, 70:529-542. 10.1016/j.ijrobp.2007.08.034, 18207031.